Status:
COMPLETED
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
These are tumors which expresses estrogen receptors. Estrogen receptors are found within breast cancer cells and are an important marker of which medicines may best treat a breast cancer. This study i...
Eligibility Criteria
Inclusion
- Patients with histologic/immunochemical proof of ER+ primary or metastatic malignancy (positive staining in ≥ 1% of cells by immunohistochemistry).
- Patients who are to be treated with clinically approved or experimental regimens where ER has an important role
- ECOG performance status of 0-2.
- Patients must provide written informed consent
Exclusion
- Age \<18 years
- Patients who cannot undergo PET/CT scanning (i.e. because of weight limits, claustrophobia)
- Pregnancy or lactation
- Total serum bilirubin \> 1.5 times upper limit of normal (abnormal hepatic metabolism may interfere with FES hepatic excretion). Increased serum bilirubin due to Gilbert's syndrome is permitted.
- Serum creatinine \> 1.5 times upper limit of normal.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 3 2024
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT01916122
Start Date
August 1 2013
End Date
April 3 2024
Last Update
April 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065